Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
Viridian Therapeutics shares jumped 6.4% to a 52-week high Wednesday, defying a broader market decline. The move comes as investors await the FDA’s June 30 decision on veligrotug for thyroid eye disease. Viridian was valued near $3.1 billion and reported $888 million in cash as of October.
